Gla domains as targeting agents
AssigneeBayer HealthCare LLC
InventorsMaxine BAUZON, Terry HERMISTON
Life of this patent
Estimating the term…
Abstract
The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.
Claims26
A method of targeting cell membrane phosphatidylserine (PtdS) comprising:
- (a) providing an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain;
- and
- (b) contacting said peptide with a cell surface,
- wherein said polypeptide binds to PtdS on said cell membrane.
3-45. (canceled)
A method of treating cancer in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method of treating an autoimmune disease in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method of treating a viral disease in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method of treating a hypercoagulation disorder in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method of modulating clotting in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method of treating sepsis in a subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method of treating vaso-occlusive crisis in a sickle cell subject comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
A method treating a disorder characterized by pathologic expression of phosphatidylserine on the surface of a cell comprising administering to said subject an isolated polypeptide comprising a gamma-carboxyglutamic-acid (Gla) domain and lacking a protease or hormone-binding domain.
Dependencies are inferred from the claim text.